GUSTAVO HERRERA-BRITO: Open Payments
NPI 1447898861 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,273 in 64 payments from 13 companies in 2025. Trend: 2023 $728 · 2024 $1,023 · 2025 $1,273
Food & beverage: $1,274
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $534 |
| ABBVIE INC. | 11 | $219 |
| GlaxoSmithKline, LLC. | 12 | $142 |
| Novo Nordisk Inc | 4 | $90 |
| Phathom Pharmaceuticals, Inc. | 3 | $64 |
| Merck Sharp & Dohme LLC | 2 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| Amgen Inc. | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $18 |
Products named: BREZTRI, VRAYLAR, FARXIGA, TRELEGY ELLIPTA, NUCALA, VOQUEZNA, AIRSUPRA, XIFAXAN.
Industry payments across CT — which companies pay providers there.
